Thursday 22 March 2012

Doctor Who's' New Companion Jenna-Louise Coleman

The latest companion of "Doctor Who" has been revealed. Jenna-Louise Coleman, who is best known for her role as Jasmine Thomas on British soap "Emmerdale", has been cast to star opposite titular character depicter, Matt Smith, on the long-running sci-fi series.


Gushing about Coleman's character, executive producer Stephen Moffat said when announcing the casting news, "It's not often the Doctor meets someone who can talk even faster than he does, but it's about to happen." He coyly added, "Jenna is going to lead him on his merriest dance yet. And that's all you're getting for now."


"Who she's playing, how the Doctor meets her, and even where he finds her, are all part of one of the biggest mysteries the Time Lord ever encounters. Even by the Doctor's standards, this isn't your usual boy-meets-girl," he went on teasing.


on British soap Emmerdale, set in a fictional village in Yorkshire Dales, appearing in more than 150 episodes from 2005-09. On the ITV series, Coleman played Jasmine Thomas. She was nominated at the British Soap Awards for best newcomer one year and also was included in the most popular newcomer category at the National Television Awards. In 2009, she was also nominated in several categories, including best actress and sexiest female at the British Soap Awards.
She appeared in Captain America: It was a small role, but Coleman appeared as Connie in 2011's summer blockbuster Captain America: The First Avenger, which starred Chris Evans. It also marked her big-screen debut.
She co-stars in Julian Fellowes' Titanic miniseries: She plays Annie Desmond in the four-part miniseries Titanic. In an interview with The Guardian, Coleman described her character as a "cheeky little cockney." "Fellowes has given me a gift," she said. "I'm the Eliza Doolittle of the ship."
She will first appear as the new Doctor Who companion later this year: Coleman is first expected to appear in her new Doctor Who role in the series' Christmas TV special.

No comments:

Post a Comment